TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04724694

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief CBT for Chronic Pain
Description: Brief CBT-CP is a manualized protocol that includes six, 30-minute sessions over the course of 6-12 weeks. Session one focuses on foundational pain education and the development of treatment goals. Session two emphasizes balanced engagement in physical activity and pleasurable events. Session three emphasizes skills training for easily implemented relaxation techniques. Sessions four and five focus on recognizing and modifying unhelpful thoughts that negatively impact pain. Session six focuses on relapse prevention and independent implementation of CBT-CP skills following treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Participants assigned to TAU will receive standard medical care from their primary care provider including pain medications, brief advice (e.g., use of relative rest, application of heat or ice, other self-care strategies), or referral to pain-related adjunctive interventions (e.g., physical therapy), as indicated.

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual
Description: Participants assigned to TAU will receive standard medical care from their primary care provider including pain medications, brief advice (e.g., use of relative rest, application of heat or ice, other self-care strategies), or referral to pain-related adjunctive interventions (e.g., physical therapy), as indicated.
Study: NCT06532500

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-MyOWL
Description: 12-sessions of CBT-MyOWL

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT-as-usual
Description: 12-sessions of CBT using Mind Over Mood or Anxiety Phobia
Study: NCT05225077

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10 MG [Farxiga]
Description: Dapagliflozin 10 mg once a day for 1 month after CAG or PCI.
Study: NCT05891015

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Intervention for Emotional Distress(MIED)
Description: Mindfulness Intervention for Emotional Distress (MIED) program provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
Study: NCT03920462

Intervention type: DEVICE
Group type: OTHER
Intervention: Programme of intelligent electric bike for health
Description: It is a programme of 6 excursions with an intelligent electric bike for health and connected vests during 1 month (two excursions per week according the weather)
Study: NCT06095934

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neo-antigen vaccine
Description: anti-PD-1 monoclonal antibody combined with neoantigen peptide vaccine and chemotherapy
Study: NCT06219967

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Activated Charcoal
Description: Activated charcoal alone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Activated Charcoal
Description: Activated charcoal mixed with cola
Study: NCT06421519

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BiPAP setting
Description: Infants in this arm of the study will each rotate through three different BiPAP settings. The following BiPAP settings will be used:~13cmH2O / 5cmH2O, 10cmH2O / 5cmH2O, 7cmH2O / 5cmH2O

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BiPAP setting
Description: Infants in this arm of the study will each rotate through three different BiPAP settings. The following BiPAP settings will be used:~13cmH2O / 5cmH2O, 10cmH2O / 5cmH2O, 7cmH2O / 5cmH2O

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BiPAP setting
Description: Infants in this arm of the study will each rotate through three different BiPAP settings. The following BiPAP settings will be used:~13cmH2O / 5cmH2O, 10cmH2O / 5cmH2O, 7cmH2O / 5cmH2O
Study: NCT06407128

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Collection of biological samples
Description: Collection of biological samples (blood sample + valve tissue sample + saliva, periodontal and feces sample)
Study: NCT05984758

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: AS-OCT imaging
Description: Image acquisition with the Optovue RTVue OCT and the Heidelberg Spectralis OCT2 machines

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Slit lamp examination
Description: SLE of anterior chamber
Study: NCT04927351

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic Medical Record Based Discharge Medication Order Set
Description: New medication discharge order set including recommended opioid quantities, adjunct pain medication
Study: NCT05097976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: 21 x 4mg tablets beginning on POD 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 21 sugar tablets beginning on POD 1 with standard management
Study: NCT04840849

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nirsevimab
Description: Drug: injection, a single fixed IM dose on day 1 only.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: injection, 0.9% (w/v) saline, a single fixed IM dose on day 1 only.
Study: NCT05968495

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renuvion APR Handpiece
Description: The Renuvion® APR (Apyx Plasma/RF) handpiece is a sterile, single use electrosurgical (monopolar) device intended to be used in conjunction with a compatible generator for the delivery of radiofrequency energy and helium plasma for cutting, coagulation and ablation of soft tissue during open surgical procedures. Radiofrequency energy is delivered to the handpiece by the generator and used to energize the electrode. When helium gas is passed over the energized electrode, a helium plasma is generated for cutting, coagulation or ablation of soft tissue during open surgical procedures. The compatible generators operate at an adjustable power of up to 40 W (expressed as 0 - 100% where 100% is 40 W) and provide an adjustable helium gas flow of 1 - 5 L/Min. APR Handpiece has a non-extendable electrode to generate helium plasma.
Study: NCT06145035

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: umbilical cord-derived mesenchymal stromal cells (UC-MSCs)
Description: The study product will consist of 100 million UC-MSCs suspended in a final volume of 60 ml given at a rate of 3.3 million cells/min. The product will be infused into vein via intravenous line placed in the arm.
Study: NCT05616572

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OncoWhiz
Description: OncoWhiz is an online educational tool designed to supplement current institutional caregiver education. OncoWhiz requires low graphical demands, has no-end user downloads, and is compatible with both desktop and mobile phones. Questions are derived from the institutional binder and are written at a fifth-grade reading level for user accessibility.
Study: NCT05124067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: patients will receive dexamethasone (0.15 mg/kg IV; maximum 5 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: patients will receive ondansetron (0.05 mg/kg IV; maximum 4 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Patients will receive dexmedetomidine (0.3 μg/kg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal Saline
Description: patients will receive normal saline.
Study: NCT06145035

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: umbilical cord-derived mesenchymal stromal cells (UC-MSCs)
Description: The study product will consist of 100 million UC-MSCs suspended in a final volume of 60 ml given at a rate of 3.3 million cells/min. The product will be infused into vein via intravenous line placed in the arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: umbilical cord-derived mesenchymal stromal cells (UC-MSCs)
Description: The study product will consist of 100 million UC-MSCs suspended in a final volume of 60 ml given at a rate of 3.3 million cells/min. The product will be infused into vein via intravenous line placed in the arm.
Study: NCT04868682

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Education Intervention I
Description: Manual-based education program provided in individual sessions.
Study: NCT06061744

Intervention type: OTHER
Intervention: Minimally invasive surgery
Description: laparoscopic or robotic surgical approach for the treatment of gallbladder cancer

Intervention type: OTHER
Intervention: Minimally invasive surgery
Description: laparoscopic or robotic surgical approach for the treatment of gallbladder cancer
Study: NCT04868682

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Education Intervention II
Description: Manual-based education program provided in individual sessions.
Study: NCT06529003

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS) unit
Description: All participants in this study will receive the standard of care, which includes oral ibuprofen and a paracervical block at the time of laminaria insertion. Those in the treatment group will receive an adjunctive TENS unit with specific instructions for use in the interval between laminaria insertion and dilation and evacuation the next day. TENS is a non-invasive, inexpensive, over-the-counter, nonpharmacologic option to relieve pain. All participants will be provided with 15 tabs of ibuprofen 200 mg for outpatient pain control after the procedure. Participants will be instructed to take 600-800 mg of ibuprofen with food every 6 hours as needed for pain during the time period after laminaria insertion and before dilation and evacuation surgery, which is generally less than 24 hours.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in the placebo group will be given a TENS unit without a battery with similar to the intervention group but will be advised that they may or may not feel a sensation from the electrodes. All participants will be provided with 15 tabs of ibuprofen 200 mg for outpatient pain control after the procedure. Participants will be instructed to take 600-800 mg of ibuprofen with food every 6 hours as needed for pain during the time period after laminaria insertion and before dilation and evacuation surgery, which is generally less than 24 hours.
Study: NCT05219149

Intervention type: BEHAVIORAL
Intervention: Qualitative Interviews
Description: Conduct qualitative interviews with patients and families who are considering treatment options for new or recurrent CNS tumors to identify specific barriers to full participation in treatment and clinical trial enrollment (e.g., transportation, childcare, ancillary expenses). Qualitative interviews will be structured to comprehensively address potential barriers but also open-ended to give patients and families freedom to discuss a wide range of challenges.
Study: NCT05136222

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention polysomnography
Description: Please refer to 'Arms: Intervention' section.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham polysomnography
Description: Please refer to 'Arms: Control' section.
Study: NCT05327660

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Quitline Treatment as Usual (TAU)
Description: Quitline TAU is services provided by the state quitline and includes phone coaching, nicotine replacement, supplemental materials (e.g., text messaging, online content).

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Quitline Treatment as Usual (TAU)
Description: Quitline TAU is services provided by the state quitline and includes phone coaching, nicotine replacement, supplemental materials (e.g., text messaging, online content).

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Quitline Treatment as Usual (TAU)
Description: Quitline TAU is services provided by the state quitline and includes phone coaching, nicotine replacement, supplemental materials (e.g., text messaging, online content).

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Remote Carbon Monoxide (CO) Monitoring
Description: Remote CO monitoring includes a smartphone app and a remote carbon monoxide monitor. The app tracks and prompts daily use of the CO monitor.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Incentivized Remote CO Monitoring
Description: Incentivized remote CO monitoring includes a smartphone app and a remote carbon monoxide monitor. The app tracks and prompts daily use of the CO monitor and delivers small monetary incentives for each use of the CO monitor.
Study: NCT05914077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secretin
Description: Secretin will be administered intravenous during 1 minute at a dose of 0,2 μg/Kg previous to the endoscopic procedure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secretin
Description: Secretin will be administered intravenous during 1 minute at a dose of 0,2 μg/Kg previous to the endoscopic procedure.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic aspiration
Description: Endoscopic aspiration of duodenopancreatic juice after secretin stimulation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic aspiration
Description: Endoscopic aspiration of duodenopancreatic juice after secretin stimulation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound-guided fine needle aspiration
Description: Endoscopic ultrasound-guided fine needle aspiration of intraductal papillary mucinous intraductal neoplasia (IPMN).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound-guided fine needle aspiration
Description: Endoscopic ultrasound-guided fine needle aspiration of intraductal papillary mucinous intraductal neoplasia (IPMN).
Study: NCT06549504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG2202T
Description: AG2202T Single-dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AG2202R
Description: AG2202R Single-dose
Study: NCT05663177

Intervention type: DRUG
Intervention: Almonertinib and metronomic oral vinorelbine
Description: Ametinib 110mg once a day; Oral Vinorelbine 40mg three times a week for three weeks and Q28d for one course.
Study: NCT05483712

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brass Mesh Bolus
Description: During a standard-of-care 15 fraction radiotherapy treatment, a brass mesh bolus will be used for a single fraction. Small in-vivo dosimeters will be used for three treatment fractions to measure and compare skin doses for quantification purposes.
Study: NCT04547634

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Exercise and Education
Description: The intervention will consist of 30 minutes of strength exercises followed by 20 minutes of endurance with aerobic training, individualized based on the evaluations of muscular strength and endurance. Sessions lasted 1 hour, carried out twice a week, for 12 weeks. This intervention will be complemented by nutritional education.
Study: NCT05017987

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATB-101, ATB-1011, ATB-1012
Description: 1. Test drug~   - Code name: ATB-101~2. Control drug1~   * Code name: ATB-1011~  * Active ingredient: Olmesartan~3. Control drug2~   * Code name: ATB-1012~  * Active ingredient: Dapagliflozin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATB-101, ATB-1011, ATB-1012
Description: 1. Test drug~   - Code name: ATB-101~2. Control drug1~   * Code name: ATB-1011~  * Active ingredient: Olmesartan~3. Control drug2~   * Code name: ATB-1012~  * Active ingredient: Dapagliflozin
Study: NCT05283122

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mostafa Maged Technique
Description: pfannestiel incision . dissection of the bladder downwards , and Ligation of the uterine arteries on both sides then , we turn over the upper part of the lower uterine segment onto the lower part of the lower uterine segment from the inside of uterine cavity .We do this turnover (flipping ) by our hands and holding the imaginary line by two Allis forceps and by making three knots by three needles in the lower edge of the uterine incision and we enter the needles of simultaneously into the lower segment through the uterine cavity , at the same level of , the inside wall of lower uterine segment to drag the upper (half) part of the lower uterine segment on the lower part of lower uterine segment ( sandwich - like ) Third , we stitch the both sides of the flipped lower uterine segment , then we do plication of the anterior lower uterine segments to strengthen the wall of the flipped lower uterine segment and place a drain in the doglus pouch
Study: NCT04974385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: Validate the analgesic efficacy of admixed LB + bupivacaine compared with plain bupivacaine when injected for ISNB for total shoulder arthroplasty.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Active comparator as standard of care.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Active comparator as standard of care.
Study: NCT06294223

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exercise follow up with near-infrared spectroscopy
Description: Exercises will be followed by near-infrared spectroscopy. Fatigue protocol will be applied.
Study: NCT06082635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TGRX-326
Description: Subjects will be treated with the investigational drug TGRX-326 at 60 mg once a day in 28-day cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crizotinib
Description: Subjects will be treated with the control drug crizotinib at 250 mg twice a day in 28-day cycles
Study: NCT06045208

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Foot exercise
Description: This group will engage in an 8-week foot intrinsic strengthening training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lower Extremity Exercise
Description: This group will engage in an 8-week lower extremity strengthening training
Study: NCT04320251

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cochlear implant revision surgery
Description: Observation during routine cochlear implant revision surgery
Study: NCT05189444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: 20mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: 0.75g tid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: 20mg bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: 1.0g bid
Study: NCT05784259

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transdiagnostic single-session treatment
Description: Administered over 4 hour in group of 10 patients. Interventions are: Psychoeducation of emotions, De-fusion exercise, Mindfulness exercise, Interoceptive exposure, Behavioral activation
Study: NCT05189444

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: 0.5g bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth potassium citrate
Description: 0.22g bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth potassium citrate
Description: 0.22g bid
Study: NCT05982288

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Software
Description: Training of intensive care nurses with virtual reality software
Study: NCT06036355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral NMN combined with DC cell vaccine
Description: The whole intervention cycle was treated with NMN (Vital NAD) 600mg/day for at least 50 days. During this period, the first DC cell injection was given on the 10th day, and then another DC cell injection was given at 2 weeks, 4 weeks and 6 weeks after the first injection.
Study: NCT06221761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: not using antibiotic
Description: no antibiotic application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: using antibiotic
Description: antibiotic application
Study: NCT04981639

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IVPCA
Description: Intravenous patient controlled analgesia will be performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP
Description: Transversus abdominis plane block will be performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IMS
Description: Intramuscular electrical stimulation will be performed.
Study: NCT05864430

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Face-to-face Training Group
Description: The training will take approximately 3 hours. The training will be done interactively, allowing students to talk to each other and ask questions, and will end with 10 minutes of time for students' questions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DataMatrix supported Face-to-face training group
Description: Students will follow the lesson with the QR code given simultaneously with the training given during the education process. The training will be held in such a way that the students will be given the opportunity to ask questions and will end with 10 minutes of time to be given to the questions of the students.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online training group
Description: The training will take approximately 3 hours. The training will be done interactively, allowing students to talk to each other and ask questions, and will end with 10 minutes of time for students' questions.